The article aims to provide an updated and evidence-based review of the innovative electronic health interventions to monitor and improve inhaler technique and adherence to recommended therapy in asthma.
INTRODUCTION
Asthma represents a major health and socioeconomic concern worldwide [1] . It is characterized by persistent airway inflammation, bronchial hyper-responsiveness, and a variable degree of airflow obstruction, which lead to respiratory symptoms that vary in terms of frequency and severity over time [2] . For a long time, clinicians have classified and managed asthma according to severity. However, disease severity is largely affected by external factors and comorbidities [3] . Furthermore, lung function parameters, clinical symptoms and airway inflammation are not always related [4, 5] . Therefore, it has been recommended that optimal asthma management should mainly aim to achieve and maintain disease control [1] . The concept of asthma control is central to all guidelines and its degree should be assessed as the result of the current degree of clinical symptoms and the future risk of exacerbations. However, asthma control is a complex and multiparametric issue that is greatly affected not only by clinical, functional, and inflammatory parameters, but also by the education and involvement of patients.
Uncontrolled asthma is responsible for impaired quality of life, increased number of emergency visits, and hospitalizations, and disproportionate use of healthcare resources [6] [7] [8] . Despite progresses in the understanding of the patho-physiological mechanisms [9] , the disease remains uncontrolled in a vast proportion of patients [10] [11] [12] . Variable response to standard treatment has been related to distinct asthma phenotypes and endotypes [9, 13] .
However, the evidence of poor disease control despite novel and targeted treatments [14] represents a clinically relevant unmet need and has led to explore alternative causes.
Patient adherence to prescribed treatment has been shown to represent a crucial link between effective therapy and improved disease outcomes. However, several studies have revealed unsatisfactory compliance with guideline recommendations [15] and a significant underuse of asthma therapy [16] . Adherence to inhaled corticosteroids (ICSs) has been reported to be an independent strong predictor of long-term asthma control in children [17] . Moreover, a significant proportion of adult patients with difficult-to-control asthma showed poor adherence to corticosteroid therapy [18] . A recent systematic review highlighted that good treatment adherence tended to be associated with a lower risk of severe asthma exacerbations in both adult and paediatric populations [19] .
Inhalation therapy represents the mainstay of asthma treatment. Inhaler devices offer advantages such as portability, rapid onset, and local action, and minimal side effects compared to systemic drug delivery [20] . Appropriate inhalation technique is critical for optimal delivery of drugs to the airways [21] . The most common inhaler devices are metered dose inhalers (MDIs) and dry powder inhalers (DPIs); however, there are more than 200 different inhaler combinations causing significant confusion amongst patients and healthcare prescribers [22] . Many patients with asthma show a high level of improper inhalation technique [23, 24] . The CRIT-IKAL study revealed that insufficient inspiratory effort was extremely common in DPIs users (up to 38%) and was associated with uncontrolled asthma and an increased exacerbation rate [25] . In MDIs users, actuation before inhalation was also related with uncontrolled asthma. Furthermore, it has been reported that up to 85% of healthcare professionals and prescribers do not seem able to perform and teach proper inhalation technique [26] .
The electronic management of health (e-health) is a concept that emerged in the late 1990s, [27] defining an area at the intersection of medical informatics, public health, and business, aimed to deliver or enhance health services and information, through internet and related technologies [28] . E-health includes a broad range of subdomains such as mobile health (m-health), electronic reminders, telemedicine, medication trackers, and clinical decision support systems [29] . E-health has been shown to enhance the quality of care, improve adherence to therapy and allow early detection of worsening in chronic diseases [30] . In asthma, e-health might empower patients with tools and skills to become optimal self-managers [31] . E-health might also allow proactive care by providing easy-to use and personalized asthma action plans [29, 31] . Furthermore, healthcare professionals may find e-health interventions valuable tools to actively interact with patients and facilitate information exchange [32] . Finally, the use of e-health is becoming widespread in pharmaceutical industry and research.
The present article aims to provide a 'state of the art' review of the innovative electronic health methods to monitor and improve inhaler technique and adherence to recommended therapy in asthma. Electronic searches were undertaken in Medline, from the date of inception to July 2017, using the following combination of keywords: 'asthma', and 'monitor' and ('adherence' or 'device' or 'inhaler'). Original studies written in English and published in full text in the last 10 years, primarily addressing the review aim, were considered eligible for inclusion. Reference lists of included studies, recent reviews and trial registration websites (i.e. clinicaltrials.gov, eudract.ema.europa.eu) were also screened for further relevant records.
RESULTS
The search strategy yielded 290 articles. Twenty-one manuscripts satisfied the review inclusion criteria and are discussed in detail below by grouping them according to the e-health subdomains of competence [28] .
MOBILE HEALTH
In a proof-of-concept study, adult patients with asthma with poorly controlled asthma were enrolled to test, over a 4-month period, a smartphone app
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specifically designed to improve asthma control [33] . Patients interacted with the app when prompted by alerts and by patient-initiated actions such as information inquiries and data entry. The asthma control test (ACT) was used as the primary endpoint to assess disease control over intervention. A retrospective chart review was also used to evaluate changes in lung function and prescribed courses of systemic corticosteroids. Patients showed a significant improvement in ACT scores and forced expiratory volume in first second (FEV1) values over the study period, although the number of systemic corticosteroid courses decreased from 0.5 to 0.3. Fifty-eight out of 60 patients reported high satisfaction towards the mobile app.
Simpson et al. [34 & ] assessed the perspectives of individuals with asthma and healthcare professionals on the use of mobile health (m-health) interventions for asthma self-management. Focus group questionnaires were distributed to subjects with asthma and healthcare professionals. Participants identified 12 different potential applications of m-health (such as replace check-ups, advise when to seek medical attention, monitor asthma over time, collect data to present to healthcare professionals, provide education materials and instructions, record side effects). Questionnaire results showed that individuals with asthma most frequently requested m-health systems to monitor asthma over time (72%) and to collect data to present to their healthcare teams (70%). In contrast, healthcare professionals mostly selected a system alerting patients to deteriorating asthma control (86%) and advising them when to seek medical attention (87%).
In a study evaluating the feasibility and acceptability of a novel m-health management system composed of a sensor device connected to a mobile phone app designed to monitor and improve medication adherence, seven adolescents with asthma were enrolled [35] . Five patients completed the study, whereas two were lost to follow-up. Successful upload of real-time data from six of seven inhaler sensors to the server supported the feasibility of athome patient monitoring using the device. All mobile app users who completed the study reported interest in continuing to use the management system and would recommend the app to their friends. Unstructured interviews and focus groups revealed that patients felt that the intervention helped their perception of asthma control.
The ADolescent Adherence Patient Tool (ADAPT) randomized controlled trial (RCT), aims to develop an m-health intervention to support asthma selfmanagement and to evaluate the effectiveness in improving medication adherence and disease control in adolescents [36] . The ADAPT intervention consists of an interactive smartphone app, connected to a desktop platform for healthcare providers. Adherence, measured by patients' self-report and refill from pharmacy dispensing records will be the main outcome, whereas secondary measures will assess asthma control, illness perceptions, medication beliefs, and asthma-related quality of life.
An automated device for asthma monitoring (ADAM) using a consumer mobile device as a platform to facilitate continuous and objective symptom monitoring was tested in adolescents [37] . A total of 84 patients aged 13-17 years participated in the study. Participants used ADAM for 7 consecutive days completing an asthma diary two times a day. Correlation and multiple regression analyses were used to examine the relationships between ADAM data and asthma control, quality of life, and healthcare utilization at the time of the trial and 3 months later. ADAM data were negatively associated with FEV1, forced vital capacity (FVC), and asthma control, while positively related with daily activity limitation, night-time and day-time symptoms, and healthcare utilization. Device data were also a significant predictor of asthma control, quality of life, and healthcare utilization at 3 months.
In contrast, in adults, an ongoing multicentre EU Horizon 2020 funded study aims to determine to what extent physiological, behavioral, and environmental data, obtained by mobile healthcare and home-monitoring sensors, can be used to predict episodes of uncontrolled asthma and the onset of asthma exacerbations [38 & ]. Adult patients currently on controller medication, with uncontrolled asthma and/or one exacerbation in the past 12 months will be monitored in a 1-year observational study and provided with m-health and home-monitoring systems to record daily measurements for the firstmonth and weekly measurements during a followup period of 11 months.
ELECTRONIC REMINDERS
Audio-visual reminder devices have been used to investigate adherence with ICS therapy in asthma [39] . In an open-label parallel group RCT, 110 adult patients were randomized to receive 24 weeks of fluticasone propionate with or without an audiovisual reminder function (AVRF). All MDIs had electronic hidden adherence monitors. The primary outcome was adherence over a 12-week period. The study observed that the proportion of medication taken was significantly greater in the AVRF group (93%) compared with the control group (74%). Similarly, the share of patients taking more than 50%, more than 80%, or more than 90% of their medication was significantly higher in the AVRF group.
Chan et al. investigated, in a RCT, whether the use of an inhaler with audio-visual reminders led to improved adherence and asthma outcomes in school-aged children on regular ICS and presented to the emergency department with an asthma exacerbation [40 && ]. Patients were randomly assigned to receive an electronic monitoring device for use with their preventer inhaler with audio-visual reminder functions either enabled or disabled and followed-up every 2 months for 6 months. The primary outcomes were adherence to preventive ICS and number of days absent from school for any reason, although asthma control was assessed as a secondary outcome. The study reported median percentage adherence was 84% in the intervention group compared with 30% in the control group (P < 0.0001). The change in asthma morbidity score from baseline to the end of the study was significantly greater in the intervention group with a reduction of 2.0 points, compared with 1.2 points in the control group.
In a multicentre RCT aimed at studying the effects of real-time medication monitoring with short message service (SMS) reminders on adherence to ICS, 209 children were recruited from five outpatient clinics and studied for 1 year [41 & ]. Outcome measures were adherence to ICS, asthma control, quality of life, asthma exacerbations, and cost-efficiency. The authors noted mean adherence was significantly higher in the intervention group (69.3 vs. 57.3%) and no difference was found for asthma control, quality of life, asthma exacerbations, or costs.
The impact of a website and SMS reminder system (MyMediHealth) on medication adherence and self-management was assessed also in adolescents with asthma [42] . Eighty-nine patients were enrolled in a RCT. Adolescents assigned to MyMediHealth (n ¼ 46) were asked to create a medication schedule, and received SMS reminders accordingly for 3 weeks. In the other arm, control subjects received action lists as a part of their usual care. Main outcome measures included website usage patterns and self-report of system usability, medication adherence, asthma control, self-management, and quality of life. Compared to controls, improvements were found in self-reported medication adherence, quality of life, and self-management. Participants reported high satisfaction with the reminder system. However, the extent of system usage was highly heterogeneous.
In children aged 6-15 years, presenting with asthma to the hospital emergency department and prescribed ICS, the performance and acceptability of an electronic inhaler monitoring device was investigated [43] . Participants were randomized to receive a device with reminder features enabled or disabled for use with their preventer and questionnaires on device acceptability, utility, and ergonomics were completed at 6 months. Acceptability scores were high, with significantly better scores in the reminder than nonreminder group (P < 0.001). Most of the patients rated the device easy to use, effective on medication adherence, and asthma control.
TELEMEDICINE
An investigational electronic medication sensor attached to the inhaler device was assessed in 30 patients with asthma who were monitored for inhaled short-acting b2 agonist (SABA) use over a period of 4 months [44] . Participants completed surveys to assess their asthma control at entry and monthly thereafter. After the first month, participants received weekly E-Mail reports for 3 months where the reports summarized inhaled bronchodilator use during the preceding week and provided advice, derived from National Asthma Education and Prevention Program guidelines, about how to improve asthma self-management. The mean ACT score was 17.6 at entry and 18.4 at completion of the first month (P ¼ 0.66). However, after participants started receiving E-Mail feedback and online information about their inhaler use, mean ACT scores increased by 1.4 points for each subsequent study month. In parallel, significant decreases were observed in 2-week history of day-time and nighttime symptoms.
A telemedicine intervention for facilitating correct patient self-management of asthma by providing a data-driven feedback and personalized educational guidance was evaluated [45] . The objective monitoring in the use of inhaled medications was undertaken using an integrated sensor capturing date, time, and number of uses, and then transmitting the information via Bluetooth to a paired smartphone app that recorded the location of the event and securely uploaded data to remote servers. A total of 495 patients were enrolled in parallel arms for 1-year monitoring of SABA use where patients in the intervention group received access to and feedback from the system and control patients, although fitted with sensors, did not receive any feedback. Compared with control subjects, the telemedicine system significantly decreased SABA use and increased SABA-free days. Furthermore, although ACT scores were not significantly different between groups in the whole study population, patients whose asthma was initially uncontrolled, showed a greater improvement in the interventional arm.
An ongoing RCT aims to compare standard care with the use of telehealth (MASTERY) for remotely monitoring lung function and optimizing asthma control during pregnancy [46] . The intervention includes a mobile application supported by a Bluetooth-enabled handheld device for self-monitoring of lung function (FEV1, FEV6) twice daily and recording asthma symptoms and medication usage weekly, and a written asthma action plan. The primary outcome measure is change in asthma control measured using the Asthma Control Questionnaire. Secondary outcomes include changes in miniAsthma Quality of Life Questionnaire score, lung function, asthma-related health visits, days off work/study, and oral corticosteroid use. Outcome data will be collected at baseline, 3 and 6 months by an operator masked to group allocation. Maternal and neonatal outcomes will be also collected postpartum.
An interactive, engaging website for children with asthma was developed to promote adherence to asthma medications, offer a platform for teamwork between caregivers and patients, and provide primary care professionals with up-to-date symptom information and data on medication use [47] . Fiftyeight children with persistent asthma were randomized to either usual care or BostonBreathes. Patients completed asthma education activities, and reported their symptoms and medication use. Primary care providers used a separate interface to monitor their patients' website use, their reported symptoms and medication use, and were able to communicate online via a discussion board with their patients and with an asthma specialist. After 6 months, reported wheezing improved significantly in both groups, whereas there were significant improvements only in the intervention group in night-time awakenings and parental loss of sleep. Among the subgroup of patients with lower medication use at baseline, adherence improved significantly only in the intervention group.
INHALER TRACKERS
In a 24-week RCT of 303 patients with asthma, the performance of an inhaler electronic device that recorded date, time and number of actuations, was conducted in a real-world setting [48] . All monitors were loaded with study medication canisters and tested at the coordinating trial site before patient use (prestudy use checks). Within-study checks, performed before visits two to four, included a computerized check of monitor clock functions, actuation accuracy and battery life. Two thousand six hundred and seventy-eight out of 2728 monitors (98.2%) passed prestudy use checks. Of 2642 monitors dispensed to participants, 76 (2.9%) failed within-study monitor checks, 51 (1.9%) malfunctioned before data upload -mostly as a result of fluid immersion, and 93 (3.5%) were lost or discarded by participants. Complete data were available from 2498 of 2642 dispensed monitors (94.5%) and 2498 of 2549 returned monitors (98.0%).
The accuracy of an inhaler tracker recording actuations from a dry powder inhaler device (turbuhaler) was assessed over a 12-week period by using 20 monitors attached to the base of the inhalers [49] . Patterns of 'low-use' (two sets of two actuations on the same day) and 'high-use' (two sets of eight actuations on the same day) were laboratory tested. The date and time of actuations were recorded in a paper diary and compared with data uploaded from the monitors. A total of 2800 actuations were performed. Monitor sensitivity was 99.9% with a lower 97.5% confidence bound of 99.6%. The positive predictive value was 99.9% with a 97.5% lower confidence bound of 99.7%. Accuracy was not affected by whether the pattern of inhaler use was low or high, or there was a delay in uploading the actuation data.
In a similar study, 20 monitors attached to MDI SABA were used to determine their accuracy in recording actuations. Laboratory testing was performed over a 10-week period [50] . Inhaler actuations were recorded in a paper diary, which was compared with data uploaded from the monitors. A total of 2560 actuations were performed during the study period. Monitor sensitivity for diaryrecorded actuations was 99.9% with a lower 97.5% confidence bound of 99.7%. The positive predictive value for diary-recorded actuations was 100% with a 97.5% lower confidence bound of 99.9%.
The reliability of an inhaler tracker for MDIs was conducted where the accuracy of the actuation log and device functionality (i.e. monitor, buttons, menu) were tested [51] . Patients with asthma field-tested the inhaler tracker device for 7 days and recorded actuations in a diary. Uploaded data were compared to MDI dose counter and patient diaries. Baseline quality control showed that 9 of 10 devices had 100% accuracy. Eight devices were fieldtested by asthma patients and one failed predispensing testing because of an electrical circuit failure. Mean actuation log accuracy was 97% and reminders were 100% accurate. All devices successfully uploaded data. Average patient-rated difficulty of use was 6 of 100.
In another study, 18 participants from a 6-month cluster RCT who received reminders for missed doses via an inhaler tracker adherence monitor were interviewed to explore their feedback on feasibility, utility, and sustainability [52] . Overall, interviewees found the use of reminders and adherence feedback acceptable and useful for improving their adherence and confidence in asthma self-management.
CLINICAL DECISION SUPPORT SYSTEMS
An ongoing prospective, randomized, multicentre study will assess whether incorporating objectively recorded adherence and lung function into clinical decision making achieves more cost-effective prescribing and improves disease outcomes in patients with severe uncontrolled asthma [53] . Data on adherence, inhaler technique, and electronically recorded peak expiratory flow rate will be used to promote adherence and guide a clinical decision protocol to guide management in the active group. The control group will receive standard inhaler and adherence education. The primary outcome is the between-group difference in the proportion of patients who have refractory disease and are prescribed appropriate medications at the end of 32 weeks with co-primary outcome the difference between groups in the rate of adherence to ICS/ LABA inhaler over the last 12 weeks. Secondary outcomes include changes in symptoms, lung function, type-2 cytokine biomarkers, and clinical outcomes between both groups.
CONCLUSION
Collected evidence supports a relevant role for ehealth in monitoring and improving inhaler use and treatment adherence in asthma. Significant positive effects have been shown on disease control, treatment adherence, medication use, self-management and patient-healthcare provider interactions. The patients' feedback on the feasibility, acceptability and sustainability of the assessed interventions was also found to be positive. Existing findings appear to be of moderate-high quality, being based in many cases on robust study designs (RCT) and wide population sample size. Current ongoing studies will hopefully further strengthen the degree of evidence. Included studies mainly addressed m-health, electronic reminders, telemedicine and inhaler tracker interventions. Investigations were performed both in adult and paediatric/adolescent populations. Of interest, an ongoing randomized controlled trial is also evaluating the use of telehealth for remotely monitoring lung function and optimizing asthma control during pregnancy. Laboratory testing on inhaler sensor accuracy were also performed. Notably, 17 of 21 papers were published in the last 3 years showing a progressively increasing interest for this field of study. However, a significant number of studies were published on low-ranked scientific journals (impact factor <2). Extremely high heterogeneity was also found in the study endpoints, which were varying from severity of symptoms to use of rescue medication, lung function, exacerbations, hospital admissions, quality of life, and so on. This currently prevents from a proper comparison among studies and an organic interpretation of findings. In conclusion, e-health represents a highly valuable tool for achieving an optimal and personalized asthma management. However, there is still the need to establish unanimously agreed and adopted standards for conducting trials and reporting results on e-health in asthma, and to identify the most appropriate tools to adopt in different populations (i.e. age, level of education), in order to fully understand its real added value.
